摘要
目的 观察复方苦参注射液联合阿替利珠单抗二线治疗晚期非鳞癌非小细胞肺癌(NSCLC)患者的临床疗效及安全性。方法 选取2018年3月-2019年7月中一东北国际医院有限公司收治的60例晚期非鳞癌NSCLC患者作为研究对象,采用随机数字表法分为对照组和观察组,每组30例。对照组采用阿替利珠单抗治疗,观察组在对照组基础上予以复方苦参注射液治疗。2组均治疗12周。比较2组病情缓解率(ORR)、病情控制率(DCR),治疗前及治疗后12周肿瘤标志物[胰岛素样生长因子结合蛋白-2(IGFBP-2)、胰岛素样生长因子Ⅱ(IGF-Ⅱ)及甲胎蛋白(AFP)]水平,总生存时间、无病生存时间及不良反应发生情况。结果 观察组ORR为53.33%、DCR为56.67%,分别高于对照组的23.33%、30.00%(χ^(2)值分别为5.711、13.871,P值分别为0.017、<0.001)。治疗12周后,2组IGF-Ⅱ、AFP水平低于治疗前,且观察组低于对照组(P<0.05)。观察组总生存时间与无病生存时间长于对照组(P<0.05)。2组脱发、心功能损伤、肾功能损伤、肝功能损伤、发热、口腔溃疡、腹泻、恶心呕吐、血红蛋白下降、血小板减少发生率比较,差异无统计学意义(P>0.05)。结论 采用复方苦参注射液联合阿替利珠单抗治疗晚期非鳞癌NSCLC患者的临床疗效确切,能够有效延缓病情进展,延长患者的总生存时间与无病生存时间,且具有一定的安全性。
Objective To explore the clinical effect and safety of compound Kushen injection combined with atilizumab in the second-line treatment of advanced non-squamous carcinoma non-small cell lung cancer(NSCLC).Methods A total of60 patients with advanced non-squamous carcinoma NSCLC treated in No.1 Northeast International Hospital Co.,Ltd.from March 2018 to July 2019 were selected as the research object,and they were divided into control group and observation group by random number table method,with 30 cases in each group.Patients in the control group were treated with atilizumab,and patients in the observation group were treated with compound Kushen injection on the basis of the control group.Both groups were treated for 12 weeks.The objective remission rate (ORR),disease control rate (DCR),tumor markers (IGFBP-2,IGF-Ⅱ,AFP) before treatment and at 8 weeks after treatment,overall survival time,disease-free survival time and incidence of adverse reactions were compared between the two groups.Results The ORR,DCR of patients in the observation group were 53.33%,56.67%,respectively,which were higher than 23.33%,30.00%of the control group(χ^(2)value was 5.711,13.871,P value was 0.017,<0.001,respectively).At 12 weeks after treatment,levels of IGF-Ⅱand AFP were lower than thsoe before treatment,and the observation group were significantly lower than those in control group(P<0.05).The overall survival time and disease-free survival time of the observation group were longer than those in control group(P<0.05).There was no significant difference of the incidence of alopecia,cardiac dysfunction,renal dysfunction,liver dysfunction,fever,oral ulcers,diarrhea,nausea and vomiting,hemoglobin reduction and thrombocytopenia between the two groups (P>0.05).Conclusion For second-line treatment of patients with advanced non-squamous carcinoma NSCLC,the application of compound Kushen injection combined with atelizumab have an exactly clinical effect,and can inhibit tumor progression,extendthe overall survival time and disease-free survi
作者
刘美子
马艳
LIU Meizi;MA Yan(Department of Pharmacy,No.1 Northeast International Hospital Co.,Ltd.,Shenyang 110000,China)
出处
《临床合理用药杂志》
2022年第18期15-18,共4页
Chinese Journal of Clinical Rational Drug Use
关键词
非小细胞肺癌
晚期
非鳞癌
复方苦参注射液
阿替利珠单抗
二线治疗
Non-small cell lung cancer
Advanced
Non-squamous carcinoma
Compound Kushen injection
Atelizumab
Second-line treatment
